Evidence map›Paper›PMID 38696189›Full record

ArticleInvestigative ophthalmology & visual science2024

Quantifying Putative Retinal Gliosis in Preclinical Alzheimer's Disease.

Swetha Ravichandran, Peter J Snyder, Jessica Alber, Madelyn R Kenny, Andrew Rothstein, Keisha Brown, Charles F Murchison, Olivio J Clay, Erik D Roberson, Edmund Arthur

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Swetha RavichandranSchool of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Peter J SnyderDepartment of Neurology, Alpert Medical School of Brown University, Providence, Rhode Island, United States.
Jessica AlberDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island, United States.
Madelyn R KennySchool of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Andrew RothsteinSchool of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Keisha BrownSchool of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Charles F MurchisonAlzheimer's Disease Research Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Olivio J ClayAlzheimer's Disease Research Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Erik D RobersonAlzheimer's Disease Research Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Edmund ArthurSchool of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States.
University of Alabama at Birmingham · USBrown University · USUniversity of Rhode Island · US

Funding

Longitudinal validation of retinal biomarkers against cerebral imaging in preclinical Alzheimer's diseaseR01AG079241 · NIA · UNIVERSITY OF RHODE ISLAND · PI Jessica Alber · 2022 to 2026
$10.4M
UAB Alzheimer's Disease Research CenterP20AG068024 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROBERSON, ERIK D · 2020 to 2022
$3.3M
Characterizing Retinal Tissue Oxygenation, Structure, and Function in Alzheimer's DiseaseR21AG079794 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ARTHUR, EDMUND · 2023 to 2024
$408k
NIA NIH HHS P20 AG068024NIA NIH HHS R01 AG079241NIA NIH HHS R21 AG079794
6 · The paper itself

Abstract

Purpose: Neuroinflammation plays a significant role in the pathology of Alzheimer's disease (AD). Mouse models of AD and postmortem biopsy of patients with AD reveal retinal glial activation comparable to central nervous system immunoreactivity. We hypothesized that the surface area of putative retinal gliosis observed in vivo using en face optical coherence tomography (OCT) imaging will be larger in patients with preclinical AD versus controls. Methods: The Spectralis II instrument was used to acquire macular centered 20 × 20 and 30 × 25-degrees spectral domain OCT images of 76 participants (132 eyes). A cohort of 22 patients with preclinical AD (40 eyes, mean age = 69 years, range = 60-80 years) and 20 control participants (32 eyes, mean age = 66 years, range = 58-82 years, P = 0.11) were included for the assessment of difference in surface area of putative retinal gliosis and retinal nerve fiber layer (RNFL) thickness. The surface area of putative retinal gliosis and RNFL thickness for the nine sectors of the Early Treatment Diabetic Retinopathy Study (ETDRS) map were compared between groups using generalized linear mixed models. Results: The surface area of putative retinal gliosis was significantly greater in the preclinical AD group (0.97 ± 0.55 mm2) compared to controls (0.68 ± 0.40 mm2); F(1,70) = 4.41, P = 0.039; Cohen's d = 0.61. There was no significant difference between groups for RNFL thickness in the 9 ETDRS sectors, P > 0.05. Conclusions: Our analysis shows greater putative retinal gliosis in preclinical AD compared to controls. This demonstrates putative retinal gliosis as a potential biomarker for AD-related neuroinflammation.

Indexed as

Alzheimer DiseaseGliosisRetinal Ganglion CellsTomography, Optical CoherenceAgedAged, 80 and overFemaleHumansMaleMiddle AgedNerve FibersRetinaRetinal Diseases

Identifiers

PMID38696189
PMCPMC11077916
OpenAlexW4396658705

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.